argenx announces launch of proposed public offering in the United States
(WorldNews Netherlands)

December 11, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has commenced an underwritten U.S. public offering of $150 million of its American Depositary Shares (ADSs) (the Offering). Each of the ADSs offered in the Offering represents the right to receive one ordinary share, nominal value of EUR0.10 per share. All of the ADSs in the proposed Offering are to be sold by argenx. argenx intends to grant the underwriters of the Offering a 30-day option to purchase additional...